Skip to main content

Table 2 Scores of the Newcastle-Ottawa Scale

From: Education in the placement of ultrasound-guided peripheral venous catheters: a systematic review

Authors Study type Selection Comparability* Outcome
   Representativeness of the exposed cohort Selection of the non exposed cohort Ascertainment of exposure Demonstration that outcome of interest was not present at start of study 1) Study controls for _______ (most important factor) 1) Study controls for any additional factor Assessment of outcome Was follow-up long enough for outcomes to occur? Adequacy of follow up for cohorts
Bauman [61] Cohort study 2() 1() 1() 1() Difficult vein access () / 3 1() 4
Oakley [60] Prospective observational study 3 1() 1() 2 Difficult vein access () / 3 1() 2()
Feinsmith [52] Cohort study 3 1() 1() 1() Difficult vein access () / 2() 1() 2()
Schoenfeld [70] Prospective observational study 3 3 1() 2 Difficult vein access () / 2() 1() 2()
Blaivas [26] Prospective observational study 2() / 1() / / / 3 1() 2()
Desai [20] Cross-sectional study 2() 3 1() 1() / / 2() 1() 3
Partovi-deilami [62] Cohort study 3 1() 1() 1() On-call access team () / 2() 1() 2()
Carrie [13] Cross sectional study 2() / 3 1() / / 2() 1() 1()
Adhikari [14] Cross sectional study 2() / 1() 2 / / 3 1() 1()
Oliveira [25] Cross sectional study 3 / 1() 1() / / 3 1() 3
Erickson [45] Prospective observational study 2() 1() 1() 1() / / 1() 1() 1()
Ault [43] Cohort study 3 1() 1() 2 / / 4 1() 1()
Stolz [42] Prospective observational study 3 1() 1() 1() / / 2() 1() 1()
Gopala-singam [67] Cohort study 3 1() 1() 2 Apheresis patients () / 1() 1() 1()
Chinnock [58] Prospective observational study 4 / 1() 2 / / 4 1() 1()
Sou [64] Cohort study 2() 1() 1() 2 Difficult vein access () / 2() 1() 1()
Good [47] Cohort study 2() 1() 1() 1() / / 2() 1() 1()
Shokoohi [21] Cohort study 2() 1() 1() 2 / / 2() 1() 2()
Panebianco [18] Cohort study 3 / 1() 2 / / 2() 1() 1()
Maiocco
[66]
Observational study 3 2 1() 2 / / 2() 1() 2()
Reeves [36] Cohort study 2() ? 1() 2 Difficult vein access () / 2() 1() 4
Salleras-duran [17] Not stated (cross-sections study) 2() 1() 3 2 / / 3 1() 1()
Vinograd [71] Cohort study 3 1() 4 2 / / 2() 2 3
Dargin [72] Cross sectional study 1() / 1() 2 / / 2() 2 2()
Thorn [48] Cohort study 1() 1() 3 2 / / 2() 1() 1()
Galen [29] Cohort/case control 1() 1() 1() 1() / / 2() 2 2()
Blick [73] Observational study 2 () / 1() / / / 3 1() 1()
Anderson [41] Observational study 1() / 2() 2 / / 3 1() /
Batten [33] Cohort study 3 2 2() 1() / No previous Us experience () 2() 1() 1()
Ballard [28] Cohort study 1() 1() 1() 1() / / 2() 1() 1()
Amick [30] Prospective cohort study 2() 1() 2() 1() / / 2() 1() 2()
Bortman [74] Cohort study 3 1() 2() 1() / / 4 2 3
Kaganocskaya [75] Quasiexperimental study (prospective cohort) 3 1() 1() 2 / / 2() 1() 1()
  1. Table 2: Risk of bias assessment Newcastle-Ottawa scale [10]